Seagen Inc (SGEN)

NASDAQ
150.74
-7.93(-5.00%)
After Hours
150.74
0.00(0.00%)
- Real-time Data
  • Volume:
    1,444,814
  • Bid/Ask:
    146.00/152.92
  • Day's Range:
    148.04 - 159.52

SGEN Overview

Prev. Close
158.67
Day's Range
148.04-159.52
Revenue
1.75B
Open
158.65
52 wk Range
133.2-202.6
EPS
-1.85
Volume
1,444,814
Market Cap
27.56B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
826,831
P/E Ratio
-
Beta
0.79
1-Year Change
-15.9%
Shares Outstanding
182,855,795
Next Earnings Date
Feb 10, 2022
What is your sentiment on Seagen Inc?
or
Market is currently closed. Voting is open during market hours.

Seagen Inc Company Profile

Employees
2092

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellStrong SellBuy
Technical IndicatorsStrong BuyBuyStrong SellStrong SellSell
SummaryStrong BuyNeutralStrong SellStrong SellNeutral
  • azeem Malik
    0
    • The European Commission (EC) has granted marketing authorization for Seagen's (NASDAQ:SGEN) Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
      1
      • What is the news?
        0
        • Apprently they may be included in the S&P 500, and hence funds. Just like Tesla a few weeks back
          1
        • Ludovic Raymond Did you hold a position?
          0
      • Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
        1
        • Price drop is the result of the #1 Institutional holder (Baker Bros) selling the entire position.
          0
          • You say Baker Bros sold the entire position, 27.5%. this is not possible. not that much volume.
            0
          • Executing through a secondary offering. The company issued a press release on it.
            0
        • Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug  December 14, 2020
          0
          • 180+
            0
            • Buy buy buy
              0
              • Reports tomorrow worth a BUY? > www.tradeticker.news/sgen/
                1
                • Phase 2 data of Tisotumab vedotin would be something to watch for !!! Eventual approval by FDA is anticipated
                  1
                  • It’s a great buy at $149.. Target $185
                    0
                    • Did you hold a position?
                      0
                  • buy?
                    1
                    • Lots of pratying an thing the Lord an praising Him.an Represents of sin believe an truest in the Lord Jesus Christ an Father an the Holy spirit
                      5
                      • Think you all very much you don't a great job .be bless if it God will
                        3
                        • Powerful teaming up with Merck on cancer drug!
                          0
                          • i dont care sbout the stock but i am thankful for their work.
                            0
                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.